Fig. 2.

The N-terminal ricin A homologous domain of MAP30 is implicated in anti-EBV response A). This figure shows the schematic diagram of N-terminal peptides and mutants of MAP30. B). The increasing amount of the indicated expression vectors from 0.1 to 1 μg was co-transfected with EBNA1, oriP-Luc, and β-Gal control into BJAB cells. The mRNAs produced by each FMAP30 or mutant were determined by qPCR and the protein expression from the transfected EBNA1 plasmid was identified by Western blot analysis. C). A BJAB-EBNA1/oriP-Luc reporter cell line was applied to perform a luciferase activity assay after the cells were treated with rMAP30 or a mutant for 16 h. The purified recombinant proteins for MAP30 or mutants were resolved by immunoblotting analysis. The expression protein levels of EBNA1 or actin control in protein drug treated cells was determined by western blots.